Residents typically participate in dermatology grand rounds three times per month. After a live patient viewing, often with patients who present diagnostic or therapeutic challenges, a discussion with faculty and residents is held in a dedicated conference setting, followed by a formal lecture from a resident, faculty member or invited guest.
At this time all Grand Round Lectures are being hosted on Tuesdays at 8:30am via Zoom.
*Time may vary. Please check calendar for start time.
November 17, 2025 - 8:00am
Topic: Surgical Pearls Speaker: Tumor Board Moderator: Kira Minkis, M.D., Ph.D. This grand round will be conducted via Zoom. Link and password will be provided ahead of time. If you have any questions please contact: Mynaria Everett E: mfe3001@med.cornell.edu.
December 15, 2025 - 8:00am
Topic: Surgical Pearls Speaker: Glenn D. Goldman, MD FAHC Dermatology and Micrographic Surgery and Dermatologic Oncology University of Vermont This grand round will be conducted via Zoom. Link and password will be provided ahead of time. If you have any questions please contact: Mynaria Everett E: mfe3001@med.cornell.edu.
December 16, 2025 - 10:00am
Englander Institute for Precision Medicine Seminar Series "Multi-omic and Functional Landscapes of Melanoma Converge on Clinically Actionable Features" Presented by Mitch Levesque, PhD Full Professor of Dermato-Oncology, University of Zurich, Switzerland Co-Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland Bio: Professor Mitch Levesque is Full Professor of Dermato-Oncology at the University of Zurich, Switzerland and Co-Head of Research in the Department of Dermatology at the University Hospital Zurich. His group focuses on understanding how tumor heterogeneity and the immune microenvironment influence treatment resistance and response in melanoma. As Head of the Skin Cancer Biobank, Prof. Levesque leads one of Europe’s most comprehensive melanoma collections, integrating clinical, molecular, and functional data to accelerate biomarker discovery and precision oncology. His research has contributed to identifying molecular predictors of immunotherapy response and mechanisms of adaptive resistance to targeted therapies, with findings published in Nature Medicine, Cancer Cell, and Cell. A founding member of the Skintegrity.CH consortium and the Tumor Profiler program, he promotes close collaboration between clinicians, pathologists, and data scientists to bring high-dimensional analyses into patient care. He is also co-founder of Oncobit AG, a spin-off translating blood-based biomarker technologies for real-time monitoring of cancer therapy.
